Mealey's (April 14, 2023, 12:35 PM EDT) -- NEW YORK — A federal judge in New York ruled that lead plaintiffs in a securities class action lawsuit against drugmaker Mylan N.V. and certain of its current and former executive officers failed to sufficiently plead any elements of their federal securities law claims pertaining to alleged misrepresentations the defendants made regarding the company’s classification of its EpiPen product and concealed its involvement in an anti-competitive rebate scheme that allowed Mylan to inflate the price of EpiPen....